Lymphoma

Craig H. Moskowitz, MD, discussed the transition toward molecularly defined lymphoma care and the declining role of autologous stem cell transplantation.

Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.

A data monitoring committee recommended the halt for futility of the phase 3 FLASH2 trial evaluating synthetic hypericin in cutaneous T-cell lymphoma.

A total of 48.0% of patients treated with duvelisib experienced a response, 33.3% of whom experienced a complete response.

Alex Herrera, MD, analyzed the SWOG S1826 trial, highlighting how nivolumab plus AVD improved survival and reduced AEs in advanced Hodgkin lymphoma.

At the MRD assessment on day 45, patients with large B-cell lymphoma treated with cema-cel saw a median decrease of 97.7% in their plasma ctDNA levels.

A large community-based chart review demonstrates robust real-world responses with tafasitamab/lenalidomide across a racially diverse US population.

Although numerous bispecific agents are FDA approved for large B-cell lymphoma, many did so based on single-arm studies requiring confirmation studies.

The totality of evidence from the phase 2 ZUMA-2 study formed the basis of the regulatory decision.

The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Clinically relevant variants were detected in 64% of samples, with negative results informing response or ruling out central nervous system lymphomas.

Findings from the phase 3 SWOG 1826/CA209-8UT trial support the regulatory decision for this lymphoma population.

An independent data monitoring committee advised that the risks associated with emergent secondary hematologic malignancies may outweigh the benefits.

Peter Martin, MD, focused on the collaborative meeting setting and where the MCL research field is headed.

Kami Maddocks, MD, discusses how the push to define high-risk MCL for clinical trials was a focus at the 2025 MCL workshop.

Frontline acalabrutinib tablets have been approved by the FDA for the treatment of CLL and SLL.

Michael Wang, MD, discusses the impact of the MCL Scientific Consortium on the lymphoma community.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for tirabrutinib in this relapsed/refractory group.

The role of bispecific antibodies in mantle cell lymphoma treatment remains unclear, and they are not readily available in community sites, according to Tycel Phillips, MD.

Experts convene at the 2025 MCL Scientific Consortium to spark collaborations, advance novel therapies, and boost patient outcomes through foundation-driven research support.

Julie M. Vose, MD, MBA, details insights from the Mantle Cell Lymphoma Scientific Consortium and Workshop, focusing on global clinical trial collaboration and sequencing BTK/BCL-2 inhibitors.

TRX103 could foster a durable tolerizing environment, with regulatory cell levels matching those of healthy donors by day 42 post-transplant.

New MCL research spotlights BTK inhibitors, CAR-T advances, MRD-guided trials, and TP53-driven risk, reshaping frontline and relapse care.

Further research will investigate rates of adverse effects among patients treated with liso-cel in the real world vs a clinical trial setting.